Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline.
Raza AlikhanKeith GomezAnthony MaraveyasSimon NobleAnnie M YoungMarie Scullynull nullPublished in: British journal of haematology (2024)
A shared decision on the most appropriate agent for the treatment of cancer-associated thrombosis should consider the following factors, which should be reassessed as patients continue along their cancer care pathway: risk of bleeding; tumour site; suitability of oral medications; potential for drug-drug interactions; and patient preference and values regarding choice of drug. Continuing anticoagulation beyond 6 months in patients with cancer-associated venous thromboembolism and active cancer is recommended.
Keyphrases
- venous thromboembolism
- end stage renal disease
- atrial fibrillation
- ejection fraction
- newly diagnosed
- chronic kidney disease
- pulmonary embolism
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- direct oral anticoagulants
- case report
- emergency department
- adverse drug
- drug induced
- squamous cell
- lymph node metastasis
- climate change